IVB501

IVB501 is an investigational adeno-associated virus (AAV) based gene therapy developed by InnoVec Biotherapeutics for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The therapy is designed to utilize muscle tissue as a biological factory for the sustained expression and systemic secretion of Fibroblast Growth Factor 21 (FGF21). FGF21 is a potent metabolic hormone that regulates glucose and lipid metabolism, improves insulin sensitivity, and reduces hepatic fat accumulation. By leveraging AAV-mediated delivery to the muscle system, IVB501 aims to provide a long-term therapeutic effect through a single administration, potentially overcoming the limitations of short-acting recombinant FGF21 proteins in treating chronic metabolic disorders.